Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (Nasdaq: CLOV) is live on Kno2 and participating in CMS-aligned interoperability initiatives, enabling real-time, patient-directed responses for clinical and claims data using FHIR (USCDI v3) standards.
Participation is powered by Counterpart Health infrastructure and Kno2 routing; live demonstrations will run March 10–12, 2026 at HIMSS 2026.
Clover Health (Nasdaq: CLOV) announced it is the first payer live on a CMS Aligned Network and TEFCA for patient-directed requests, enabling real-time responses to clinical and claims data in standardized FHIR (USCDI v3) formats. Counterpart Health powers the underlying infrastructure and Kno2 routes secure requests across the network.
The milestone enables authenticated Medicare members to request and receive structured clinical and claims data in real time, and Clover, Kno2, and Counterpart will demonstrate an end-to-end response at HIMSS 2026, March 10–12 at Kno2 booth #12720.
Clover Health (Nasdaq: CLOV) reported full year 2025 results and provided 2026 guidance. Key 2025 results: $1.924B total revenues (+40% YoY), Medicare Advantage membership 113,803 (+38% YoY), GAAP net loss $85.5M, and Adjusted EBITDA $21.7M. For 2026 the company guides 154,000–158,000 average MA members, total revenues of $2.81B–$2.92B, Consolidated Gross profit $470M–$510M, Adjusted EBITDA $50M–$70M, and GAAP Net Income $0M–$20M.
Management cited improving cohort economics, Clover Assistant-driven care, and membership scaling as drivers toward first full-year GAAP profitability in 2026.
Clover Health (Nasdaq: CLOV) said CFO Peter Kuipers will present at the Leerink 2026 Global Healthcare Conference on March 10, 2026 at 9:20 a.m. ET.
A live webcast and replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) will report its fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026, and host a webcast at 5:00 p.m. Eastern Time.
The webcast will be available live and archived for 12 months on Clover Health investor relations, and registration is available via the provided webcast link.
Clover Health (Nasdaq: CLOV) reported a 53% year-over-year increase in Medicare Advantage PPO membership for the 2026 plan year, entering 2026 with ~153,000 members. The company said >95% AEP retention and that >97% of members are in its flagship PPO, which it ranks #1 nationally on core HEDIS metrics. Clover expects to achieve its first full-year GAAP net income profitability in 2026, citing improving cohort economics, SG&A leverage, a 4.0 Star payment impact, and a favorable 2026 CMS rate update.
Counterpart Health (CLOV) reported 2025 highlights showing scaled clinical impact from its AI physician‑enablement platform, Counterpart Assistant (CA). Key outcomes include a >450% YoY increase in live third‑party customer clinicians, an approximate 1,500 basis point MCR differential for returning Clover members with CA PCPs, and the PPO Medicare Advantage plan achieving the #1 HEDIS score nationwide for a second year.
Retrospective analyses found earlier COPD diagnosis (new members 75% more likely in year one), higher outpatient pulmonology use (+18%), lower all‑cause hospitalizations (CHF −18%; COPD −15%), reduced 30‑day readmissions (CHF −25%; COPD −18%), and 70–89% higher diagnosis rates in high ADI neighborhoods. Product expansions included integrated ambient scribing, natural language chat, proactive visit summaries, and broader enterprise capabilities.
Clover Health (Nasdaq: CLOV) said its CEO Andrew Toy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15 a.m. ET.
A live webcast and a replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (NASDAQ: CLOV) reported Q3 2025 results: Medicare Advantage membership 109,226 (+35% YoY) and Total revenues $496.7M (+50% YoY). Q3 profitability metrics: GAAP net loss $24.4M, Adjusted EBITDA $2.1M, and Adjusted Net income $1.7M. Year-to-date Adjusted EBITDA is $45.0M and Adjusted Net income is $43.7M. Cash and investments totaled $395.9M (down 25.5% YoY). Q3 Insurance BER rose to 93.5% from 82.8% a year earlier; Normalized Insurance BER was 92.4%.
The company raised full‑year 2025 guidance: Avg. MA membership 106k–108k, Insurance revenue $1.85B–$1.88B, Adjusted SG&A $325M–$335M, and Adjusted EBITDA $15M–$30M. Management cited cohort economics, retention, and a favorable 2026 CMS environment as drivers toward improved profitability.